Zacks Research Has Bullish Outlook for PBH FY2025 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research raised their FY2025 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $4.58 for the year, up from their previous estimate of $4.51. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2025 earnings at $1.29 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $4.76 EPS, Q1 2027 earnings at $1.09 EPS and FY2027 earnings at $5.03 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

A number of other brokerages have also recently issued reports on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.60.

Prestige Consumer Healthcare Stock Performance

PBH opened at $83.77 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The company has a market cap of $4.15 billion, a PE ratio of 19.62, a price-to-earnings-growth ratio of 2.69 and a beta of 0.50. The stock has a 50-day moving average of $79.92 and a 200-day moving average of $77.01. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $88.36.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Prestige Consumer Healthcare during the fourth quarter valued at about $7,778,000. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Vise Technologies Inc. bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $319,000. McIlrath & Eck LLC raised its stake in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Prestige Consumer Healthcare by 24.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company’s stock valued at $9,223,000 after purchasing an additional 23,334 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.